Dear EAN members,
Dear colleagues and friends,
the political landscape across Europe and around the world is currently quite shaky and experiences a lot of turmoil, confrontation and egocentric behaviour. In this situation it is comforting that the “Neurological World“ does not follow this dissolution but rather moves in the opposite direction. There is increasing readiness for close collaboration and efforts to join forces among scientific societies and these synergies are critical for convincing decision makers of the benefits of supporting health research and other measures which help to assure the well-being of Europe’s population in the future.
Category
Featured Slider
-
-
Paper of the MonthEAN NewsFeatured Slider
Paper of the month: Erenumab in preventive treatment-resistant episodic migraine
December 1, 2018For December 2018, we have selected: Reuter U, Goadsby PJ, Lanteri-Minet M, et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomized, double-blind, placebo-controlled, phase 3b study. Lancet Neurol 22 October, 2018. -
Denmark is placed in Northern Europe and is one of the three Scandinavian countries. The population is 5.7 million and Copenhagen, the capital of Denmark, is by far the largest city with a population of 1.3 million. Denmark has a total area of 42.924 km2 (16.573 sq mi).
-
Dear Colleagues, I hope that you are all looking forward to the 2019 EAN congress in Oslo, and that you are planning abstracts to submit! On October the 16th I attended an inspection visit of the congress venue, along with Franz Fazekas our president, Erik Tauboll chair of the local organizing committee, members of the EAN office team and representatives from Industry partners that are sponsoring our congress.
-
Paper of the MonthEAN NewsFeatured Slider
Paper of the month: Intrathecal stem cells for amyotrophic lateral sclerosis
November 1, 2018For November 2018, we have selected: Oh KW, Noh MY, Kwon NS, et al. Repeated intrathecal stem cells for amyotrophic lateral sclerosis. Ann Neurol 2018;84:361-373. Stem cell research is a hot topic in motor neuron disease/amyotrophic lateral sclerosis (MND/ALS) both for clinicians and patients. Whilst recognized as an important area of promise for developing future therapeutics in neurodegenerative disease, it has been much hyped in the media, and dissecting the scientific research on the subject from the many unproven approaches advertised to patients by commercially motivated companies can be challenging. -
Bulgaria is located in the Southeast of Europe, in the northeast part of the Balkan Peninsula, bordering the Black Sea. It occupies an area of 111,000 km² and it is a European, Balkan, Black Sea and Danube country. Bulgaria is a parliamentary republic with a population of 7.15 million people. Bulgaria’s first constitution was adopted in 1879 and was one of the most democratic constitutions of its time despite the previous almost five centuries of destroyed statehood.
-
Executive PageEAN NewsFeatured Slider
Executive Page: A team to face the challenges ahead
October 1, 2018Dear EAN-Members, Dear colleagues and friends, I hope that you all had a wonderful and relaxing summer, and that you have regained the energy needed for being successfully back to work after vacation. I always enjoy when the speed and intensity of daily activities reduce a little over summer, and I am sure that such times are also important for rethinking projects, developing new ideas, and enhancing our creativity. -
Paper of the MonthEAN NewsFeatured Slider
Paper of the month: Improving neuropathy in hereditary transthyretin amyloidosis by targeting mRNA transcription
October 1, 2018For October 2018, we have selected two papers. The first is: Adams D, Gonzales-Duarte A, O’Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis.(APOLLO trial). NEJM 2018;179:11-21. The second is: Benson MD, M Waddington-Cruz, JL Berk, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. (NEURO-TTR trial) NEJM 2018;179:22-31. Hereditary transthyretin amyloidosis is a rare autosomal dominant disorder in which mutations of the gene for transthyretin protein (TTR) induce systemic deposition of amyloid. -
by Prof. Dr. Serefnur Ozturk and Burak Tokdemir The Republic of Turkey is a country with an extraordinary history and the home of 80 million people. As one of the three countries in the world that span… Continue Reading
-
Executive PageEAN NewsFeatured Slider
Executive Page: American Dream 2018: Report of a Sleep Researcher
September 1, 2018In 2 weeks, my sabbatical period in the United States, which started in April 2018, will come to an end. The word sabbatical comes from “Sabbath,” which in the biblical Old Testament was described as, “In the seventh year the land shall have a Sabbath of complete rest …” Today in Academics, it is obviously not simply rest. For me it was a break after 23 years of an uninterrupted hospital and university activity, 17 of which as chair or vice-chair of large neurological departments. -
EAN NewsCountry of the MonthTop ArticlesFeatured Slider
Country of the month – Azerbaijan
September 1, 2018This is the Land of Fire and the Pearl of the Caucasus, a land where eastern colors combine magnificently with western progress. Azerbaijan is situated at the eastern side of the Transcaucasia on the shores of the Caspian Sea. The… Continue Reading -
Paper of the MonthEAN NewsFeatured Slider
Paper of the month: Apomorphine pump is effective for motor fluctuations in Parkinson’s disease
September 1, 2018For September 2018, we have selected: Katzenschlager R, Poewe W, Rascol O, et al. Apomorphine subcutaneous infusion in patients with Parkinson’s disease with persisten motor fluctuations (TOLEDO): a multicenter, double-blind, randomized, placebo-controlled trial. Lancet Neurol July 25, 2018. doi:10.1016/S1474-4422(18)30284-4. Subcutaneous infusion of apomorphine, a potent dopamine receptor agonist, is widely used in patients with Parkinson’s disease (PD) with motor fluctuations not optimally controlled with oral medication, but the previous evidence base to support this approach was weak, derived from open label studies. -
Executive PageEAN NewsFeatured Slider
Executive Page: Become a member of EAN, the ‘Home of Neurology’!
August 1, 2018The mission of EAN is ‘to promote excellence in neurology across Europe’. Therefore we need you, our colleagues, to become individual EAN members. Membership is not only for your own benefit, but also to accomplish our mission. As an individual member you can play an important role. By standing for election for the position as Delegate in the Assembly of Delegates you can become an influencer. -
Paper of the MonthEAN NewsFeatured Slider
Paper of the month: Impact of dopamine agonists dose and duration on impulse control disorders in Parkinson disease
August 1, 2018For August 2018, we have selected: Corvol JC, Artaud F, Cornier-Dequaire F, et al., for the DIGPD Study Group. Longitudinal analysis of impulse control disorders in Parkinson disease. Neurology 2018. doi:10.1212/WNL.0000000000005816. Impulse control disorders (ICDs) are frequent in Parkinson’s disease (PD) patients, and can have relevant consequences on social life. Whereas the association between treatment with dopamine agonists (DA) and the onset of ICDs is well known, there is controversy about the relationship with dose and duration of DA therapy. -
The roots of clinical neurology can be traced back to Germany. With his ”Lehrbuch der Nervenkrankheiten des Menschen“ (textbook of human nervous diseases) 1840, Moritz Heinrich Romberg (1795 – 1873) established the foundation of clinical neurology as we know it today. His work was the first and for decades the only systematic representation of neurological diseases in Europe and America, bringing him international fame and esteem.
